◆英語タイトル：Active Biotech AB (ACTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10021
◆発行会社（調査会社）：
GlobalData
◆発行日：2018年11月
◆ページ数：48
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：スウェーデン
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
Summary
Active Biotech AB (Active Biotech) is a biotechnology company that develops and commercializes pharmaceuticals in the field of inflammatory/neurodegenerative diseases and cancer. The company’s key products in development include Laquinimod (neurodegenerative diseases); Anyara (cancer); Tasquinimod (cancer); Paquinimod (Systemic Sclerosis); and SILC (autoimmune diseases). It has licensing agreements with Teva Pharmaceutical Industries, NeoTX, Ipsen, Teva Neuroscience and MediGene AG. Active Biotech is headquartered in Lund, Sweden.
Active Biotech AB (ACTI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Active Biotech AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Active Biotech AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Active Biotech AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Active Biotech AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Active Biotech AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Active Biotech AB, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
NeoTX Therapeutics Enters into Licensing Agreement with Active Biotech 11
Equity Offering 12
Active Biotech Raise USD6 Million in Right Offering of Shares 12
Active Biotech Raises USD6.1 Million in Rights Offering of Shares 13
Active Biotech to Raise USD30.4 Million in Rights Offering of Shares 14
Active Biotech Completes Private Placement Of Shares For US$42 Million 15
Active Biotech AB – Key Competitors 16
Active Biotech AB – Key Employees 17
Active Biotech AB – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Strategy And Business Planning 19
Sep 07, 2018: Teva returns laquinimod global rights to Active Biotech 19
Financial Announcements 20
Aug 09, 2018: Active Biotech – interim report January – June 2018 20
May 17, 2018: Active Biotech: Interim report January – March 2018 24
Nov 09, 2017: Active Biotech AB – Interim report January – September 2017 28
Aug 10, 2017: Active Biotech: Interim report January – June 2017 29
Apr 27, 2017: Active Biotech: Interim Report January – March 2017 31
Feb 16, 2017: Active Biotech Year-end report January – December 2016 34
Corporate Communications 38
Jun 19, 2017: Helen Tuvesson new CEO of Active Biotech from July 1, 2017 38
Product News 39
10/19/2017: Teva to Highlight New Data on Laquinimod at Joint ECTRIMS – ACTRIMS Congress in Paris 39
05/05/2017: Teva and Active Biotech Announce CONCERTO trial of Laquinimod in RRMS Did Not Meet Primary Endpoint 40
04/19/2017: Teva Pharmaceutical to Present Data on Laquinimod at 69th Annual Meeting of the American Academy of Neurology 41
04/17/2018: Teva to Present laquinimod sodium at 70th Annual Meeting of the American Academy of Neurology 42
Clinical Trials 43
Aug 01, 2018: Teva reports negative data from LEGATO-HD trial 43
Dec 01, 2017: Active Biotech announce results in ARPEGGIO Phase II trial with laquinimod in Primary Progressive MS 44
Other Significant Developments 45
Feb 15, 2018: Active Biotech: Year-end report January – December 2017 45
Dec 20, 2017: Active Biotech provides updated information about the company’s financial position 46
Dec 07, 2017: Active Biotech provides updated information about the company’s financial position – the company currently lacks funding to ensure its operations for the coming twelve-month period 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48
List of Tables
Active Biotech AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Active Biotech AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Active Biotech AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Active Biotech AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Active Biotech AB, Deals By Therapy Area, 2012 to YTD 2018 9
Active Biotech AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
NeoTX Therapeutics Enters into Licensing Agreement with Active Biotech 11
Active Biotech Raise USD6 Million in Right Offering of Shares 12
Active Biotech Raises USD6.1 Million in Rights Offering of Shares 13
Active Biotech to Raise USD30.4 Million in Rights Offering of Shares 14
Active Biotech Completes Private Placement Of Shares For US$42 Million 15
Active Biotech AB, Key Competitors 16
Active Biotech AB, Key Employees 17
Active Biotech AB, Subsidiaries 18
List of Figures
Active Biotech AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Active Biotech AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Active Biotech AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Active Biotech AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Active Biotech AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Active Biotech AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Active Biotech AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Active Biotech AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
